Synaptogenix's Alzheimer's Candidate Displays Signs Of Safety In Mid-Stage Study

by Vandana Singh, Benzinga Editor

June 9, 2021 1:25 PM | 27 seconds read | Make a Comment

Synaptogenix Inc SNPX has announced an update on its ongoing National Institutes of Health (NIH) sponsored Phase 2b trial of Bryostatin-1 for moderately severe Alzheimer's disease (AD).
To date, the Company has dosed 58 of its target 100 patients.
Additionally, the independent Data Safety Monitoring Board (DSMB) confirmed that 40 advanced AD patients had been dosed with Bryostatin without any significant safety issues.
Price Action: SNOX shares are up 0.57% at $7.05 during the market session on the last check Wednesday.

Posted In: Biotech News Health Care General Alzheimer's disease Alzheimer’s Briefs Phase 2 Trial

Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.